Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More


Nutra Pharma Partners with Henry Schein for Distribution of Nyloxin-Branded Pain Relievers
June 01, 2010

Nutra Pharma has announced that it has partnered with leading healthcare products distributor, Henry Schein, for distribution of its Nyloxin-branded pain relievers in the United States.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has partnered with leading healthcare products distributor, Henry Schein, for distribution of its Nyloxin-branded pain relievers in the United States.

Henry Schein, which ranks #339 on the Fortune 500 list, is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners. With more than 12,500 “Team Schein Members” worldwide, the Company currently serves approximately 45% of the estimated 250,000 U.S. office-based physician practices, surgical centers and other alternate-care sites. Additionally, the Company serves approximately 85% of the estimated 136,000 U.S. and Canadian office-based dental practices, dental laboratories, as well as governments and other institutions and approximately 75% of the estimated 27,000 U.S. animal health practices.

“As one of the furthest reaching and most admired distributors of healthcare products, we are pleased to partner with Henry Schein for distribution of Nyloxin in the United States,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We look forward to strengthening our Nyloxin-brand by working closely with Henry Schein to support their distribution of Nyloxin,” he said.

Nutra Pharma currently offers two pain relievers under the Nyloxin brand, Nyloxin OTC and Nyloxin Rx. Nyloxin OTC is the Company’s over-the-counter (OTC) treatment for moderate to severe (Stage 2) chronic pain. Nyloxin Rx is the Company’s prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function. Both Nyloxin OTC and Nyloxin Rx are manufactured by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, and are available as an oral spray and topical gel.

In addition, Nutra Pharma recently announced the first manufacturing release of Nyloxin Rx for marketing-related distribution. Physicians can currently request samples of Nyloxin Rx through the Healthcare Providers’ section of the Nyloxin website:

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Announcing the partnership with Henry Schein for distribution of the Nyloxin branded pain relievers should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: